Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks is expected to reach profitability without equity raises due to their transformative strategy pivot to incorporate a core royalty aggregation model, allowing for compounding of revenue-generating royalties and the retention of in-house R&D capabilities which reduces binary risk. With their strong team and a promising clinical pipeline, Zymeworks is well positioned for success in the future and is a Buy-rated stock with a 12-month price target of $58.

Bears say

Zymeworks is currently trading at a high valuation, despite its narrow pipeline and limited sales compared to its competitors in the biopharmaceutical industry. The company's investing strategy of focusing on preclinical/earlier-stage data-driven differentiation and a lack of commercial-stage assets may also make it vulnerable to clinical trial failures or difficulties in obtaining regulatory approval and commercial success. Additionally, the company's reliance on partnerships for funding and market share in its targeted areas may lead to greater uncertainty and financial risk for investors.

Zymeworks Inc (ZYME) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Buy based on their latest research and market trends.

According to 10 analysts, Zymeworks Inc (ZYME) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.